- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Keshav Bhutada becomes CEO of Shilpa Pharma Life Sciences

Shilpa Medicare Limited has announced the appointment of Keshav Bhutada, Executive Director (ED) of Shilpa Pharma Life Sciences Ltd, a material subsidiary of the company, as ED and CEO of Shilpa Pharma Life Sciences.
Keshav is a young and dynamic member of Shilpa’s leadership team, who brings in fresh energy, vision, and a deep commitment to driving innovation and sustainable growth. He is the son of Mr. Vishnukant C Bhutada, Promoter
and Managing Director of Shilpa Medicare Ltd
Keshav Bhutada shared, “I am excited and humbled to take on this responsibility. Shilpa Group has a strong legacy, and I look forward to working with our talented team to build on this foundation, embrace new opportunities, and deliver value to all stakeholders.”
Santosh Mahil will be stepping down as CEO of Shilpa Pharma Life Sciences for personal reasons.
“SPL is a strong organization with some of the best talent in the industry and a leader in APIs, polymers, and peptides. It also stands out as one of the most integrated platforms in the CDMO space. Keshav is a capable and visionary leader who will take the company forward. As I continue my professional journey outside this organization, I extend my best wishes to the entire SPL team and Keshav for continued success,” said Mahil.
As part of the overall re-organisation of group responsibilities, Madhav Bhutada has been assigned the responsibility to oversee the Group’s biologics foray spearheading the Recombinant Albumin & large-scale microbial fermentation facility operations. He also plays a pivotal role in steering growth of biosimilars vertical, contributing to selection of a robust pipeline and actively engaging in fast growing CDMO Biologics business.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751